AB0014 IMMUNE RESPONSES TO VACCINATION AGAINST HERPES ZOSTER (HZ) IN PATIENTS WITH RHEUMATIC DISEASES UNDER TREATMENT WITH JAK-INHIBITORS: OUR PRELIMINARY RESULTS

Background Shingrix is a recombinant inactive vaccine available for prevention of herpes zoster (HZ) infection, recently approved patients with rheumatic diseases under treatment JAK-inhibitors. Because its novelty, scant information on responses in immune mediated (IMRD). Objectives To investigate the antibody to HZ selected treated JAK-inhibitors (JAKi) pre- and post-Shingrix vaccination (weeks 4–6) identify factors associated reduced immunogenicity. Methods Patients JAKi underwent two series IM (0.5mL each) administered 2 months apart. Bloodwork was performed 4-8 weeks following nd dose assess post- response. Pre post response then compared using Anti Varicella Zoster Virus IgG Multiplex Flow Immunoassay (MFI). Blood lymphocyte distributions (CD3+, CD4+, CD8+, CD19+) NK cells, total serum IgM levels, VZV-IgG IgM, were investigated 4–6). Results 38 included, 79% female median age at inclusion 57±10.5 years. 21% had rheumatoid arthritis, 8% systemic lupus erythematosus, 16% psoriatic ankylosing spondylitis 5% dermatomyositis. VHZ levels subpopulations peripheral blood post-immunization are represented Table 1. Positive humoral observed 86% patients. Mean changes VHZ-IgG between pre-vaccination sera 4.6±0.33 1.8±1.98 (p<0.0001), respectively. After immunization, number T cells CD8+) remained relatively unchanged however, B (CD19+) increased significantly from 147.4±156 780.62±475.5 (p<0.0001). There 2.5-fold increase titers after immunization RA patients, 2.4-fold SLE 2-fold AP AS 3.5-fold DM, no significant difference different patients’ subgroups. multivariate regression analysis adjusted by age, gender, disease duration, treatments glucocorticoid MTX cumulative dose, showed negative correlation >65 years (β=-0.34, p 0.03), duration (β=-0.58, 0.04) (β=-0.42, 0.02). Conclusion Our preliminary results show preserved seroconversion rates antibodies concurrently CD19+ B-cells JAKi. Age>65 years, negatively correlated virus Ab Pre-vaccination Post-vaccination P value Total (mg/dL) 958±300 1328.5±308 0.04 126±98 118.5±156 0.84 VZV (Ab Index) 0.0001 0.32±2.1 1.3±3.4 0.72 CD3 (cells/mm3) 1065.5±716.5 1128±721 0.63 CD19 CD4 653±584 783±475.5 0.34 CD8 386.2±260 392.7±297.5 0.42 281.05±189 284.52±145.5 Reference [1]Källmark H, Gullstrand B, Nagel J, Einarsson Jönsson G, Kahn F, R, Bangtsson A, Bergström T, Kapetanovic M. Immunogenicity Adjuvanted Herpes Subunit Vaccine Rheumatoid Arthritis Treated Janus Kinase Inhibitors Controls: Preliminary [abstract]. Rheumatol. 2020; 72 (suppl 10). Acknowledgements: NIL. Disclosure Interests None Declared.